[{"orgOrder":0,"company":"Valneva","sponsor":"Deerfield Management Company","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Financing","leadProduct":"VLA15","moa":"Borrelia outer surface protein A","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Valneva","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Valneva \/ Deerfield Management Company","highestDevelopmentStatusID":"8","companyTruncated":"Valneva \/ Deerfield Management Company"},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"VLA1553","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Valneva \/ Not Applicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Dynavax Technologies","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"CpG 1018","moa":"TLR9","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Valneva \/ Valneva SE","highestDevelopmentStatusID":"1","companyTruncated":"Valneva \/ Valneva SE"},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"VLA15","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Valneva","amount2":0.31,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.31,"dosageForm":"","sponsorNew":"Valneva \/ Pfizer","highestDevelopmentStatusID":"8","companyTruncated":"Valneva \/ Pfizer"},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"VLA15","moa":"Borrelia outer surface protein A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0.31,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.31,"dosageForm":"","sponsorNew":"Valneva \/ Pfizer","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ Pfizer"},{"orgOrder":0,"company":"Valneva","sponsor":"Batavia Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Inactivated polio vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Valneva \/ Batavia Biosciences","highestDevelopmentStatusID":"1","companyTruncated":"Valneva \/ Batavia Biosciences"},{"orgOrder":0,"company":"Valneva","sponsor":"Dynavax Technologies","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"CpG 1018","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Valneva \/ Valneva","highestDevelopmentStatusID":"4","companyTruncated":"Valneva \/ Valneva"},{"orgOrder":0,"company":"Valneva","sponsor":"U.K. Government","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"CpG 1018","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Valneva","amount2":1.6100000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":1.6100000000000001,"dosageForm":"","sponsorNew":"Valneva \/ U.K. Government","highestDevelopmentStatusID":"4","companyTruncated":"Valneva \/ U.K. Government"},{"orgOrder":0,"company":"Valneva","sponsor":"UK Government","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"VLA2001","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Valneva \/ UK Government","highestDevelopmentStatusID":"4","companyTruncated":"Valneva \/ UK Government"},{"orgOrder":0,"company":"Valneva","sponsor":"US Government","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"Inactivated aluminum-adjuvanted JE vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0.17000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.17000000000000001,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ US Government","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ US Government"},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"VLA15","moa":"Borrelia outer surface protein A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Valneva \/ Pfizer","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ Pfizer"},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"VLA15","moa":"Borrelia outer surface protein A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Valneva \/ Pfizer","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ Pfizer"},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"CpG 1018","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Not Applicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Instituto Butantan","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Collaboration","leadProduct":"VLA1553","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0.02,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Instituto Butantan","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Instituto Butantan"},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"VLA1553","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Not Applicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"VLA15","moa":"Borrelia outer surface protein A","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Valneva \/ Valneva","highestDevelopmentStatusID":"8","companyTruncated":"Valneva \/ Valneva"},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"Aluminium hydroxide","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Not Applicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"Aluminium hydroxide","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Not Applicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"VLA1553","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Not Applicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"Whole-virus Inactivated Adjuvanted SARS-CoV-2 Vaccine","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ Not Applicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"VLA15","moa":"Borrelia outer surface protein A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Valneva \/ Pfizer","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ Pfizer"},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"VLA1553","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Not Applicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"VLA2001","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Not Applicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Dynavax Technologies","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Termination","leadProduct":"Aluminium hydroxide","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Dynavax","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Dynavax"},{"orgOrder":0,"company":"Valneva","sponsor":"UK Government","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Termination","leadProduct":"Aluminium hydroxide","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ UK Government","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ UK Government"},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"Aluminium hydroxide","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Not Applicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"Aluminium Hydroxide","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Not Applicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"VLA15","moa":"Borrelia outer surface protein A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Valneva \/ Pfizer","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ Pfizer"},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"VLA15","moa":"Borrelia outer surface protein A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Valneva \/ Pfizer","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ Pfizer"},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"Aluminium Hydroxide","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Not Applicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Goldman Sachs & Co. LLC","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Public Offering","leadProduct":"Aluminium hydroxide","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0.10000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.10000000000000001,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Goldman Sachs & Co. LLC","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Goldman Sachs & Co. LLC"},{"orgOrder":0,"company":"Valneva","sponsor":"European Commission","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"Aluminium Hydroxide","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ European Commission","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ European Commission"},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"Aluminium hydroxide","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Not Applicable"},{"orgOrder":0,"company":"Valneva","sponsor":"European Commission","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"Aluminium Hydroxide","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ European Commission","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ European Commission"},{"orgOrder":0,"company":"Valneva","sponsor":"Kingdom of Bahrain","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"Aluminium hydroxide","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Kingdom of Bahrain","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Kingdom of Bahrain"},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"Aluminium hydroxide","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Not Applicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"VLA1553","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Not Applicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Aluminium hydroxide","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Not Applicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Aluminium Hydroxide","moa":"SARS-CoV-2 virus spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ Not Applicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Aluminium Hydroxide","moa":"SARS-CoV-2 virus spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Not Applicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"VLA1553","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Not Applicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"VLA15","moa":"Borrelia outer surface protein A","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Valneva \/ Pfizer","highestDevelopmentStatusID":"8","companyTruncated":"Valneva \/ Pfizer"},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"VLA1553","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Not Applicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Aluminium Hydroxide","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ Not Applicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Scottish Enterprise","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"Aluminium Hydroxide","moa":"SARS-CoV-2 virus spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0.029999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Scottish Enterprise","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Scottish Enterprise"},{"orgOrder":0,"company":"Valneva","sponsor":"Albumedix","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2022","type":"Expanded Collaboration","leadProduct":"Aluminium Hydroxide","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Valneva","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Valneva"},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Aluminium Hydroxide","moa":"SARS-CoV-2 virus spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Not Applicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Deerfield Management Company","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Financing","leadProduct":"Aluminium hydroxide","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Deerfield Management Company","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Deerfield Management Company"},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"VLA15","moa":"Borrelia outer surface protein A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Pfizer","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ Pfizer"},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Aluminium Hydroxide","moa":"SARS-CoV-2 virus spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Not Applicable"},{"orgOrder":0,"company":"Valneva","sponsor":"European Commission","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Termination","leadProduct":"Aluminium Hydroxide","moa":"SARS-CoV-2 virus spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Valneva \/ European Commission","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ European Commission"},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Aluminium Hydroxide","moa":"SARS-CoV-2 virus spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Not Applicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"VLA1553","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Not Applicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Aluminium Hydroxide","moa":"SARS-CoV-2 virus spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Not Applicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"VLA15","moa":"OspA","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Valneva \/ Pfizer","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ Pfizer"},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"VLA1553","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Not Applicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Financing","leadProduct":"VLA15","moa":"OspA","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Valneva","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.10000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Valneva \/ Pfizer Inc.","highestDevelopmentStatusID":"8","companyTruncated":"Valneva \/ Pfizer Inc."},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Aluminium Hydroxide","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Not Applicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Aluminium Hydroxide","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Not Applicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"VLA15","moa":"OspA","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Valneva \/ Pfizer","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ Pfizer"},{"orgOrder":0,"company":"Valneva","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"Inactivated Japanese Encephalitis Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0.12,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.12,"dosageForm":"Injectable\/Injection","sponsorNew":"Valneva \/ U.S. Department of Defense","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ U.S. Department of Defense"},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"VLA1553","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Not Applicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Aluminium Hydroxide","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Not Applicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Aluminium Hydroxide","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Not Applicable"},{"orgOrder":0,"company":"Valneva","sponsor":"VBI Vaccines","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Partnership","leadProduct":"3-antigen Hepatitis B Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Valneva \/ VBI Vaccines","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ VBI Vaccines"},{"orgOrder":0,"company":"Valneva","sponsor":"IDT Biologika GmbH","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Termination","leadProduct":"Aluminium Hydroxide","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.040000000000000001,"dosageForm":"Injection","sponsorNew":"Valneva \/ Valneva","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Valneva"},{"orgOrder":0,"company":"Valneva","sponsor":"Goldman Sachs","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Public Offering","leadProduct":"VLA15","moa":"OspA","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.10000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Valneva \/ Goldman Sachs","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ Goldman Sachs"},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"VLA1553","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Not Applicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"VLA15","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Valneva \/ Pfizer","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ Pfizer"},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"VLA1553","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Not Applicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Goldman Sachs","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Public Offering","leadProduct":"VLA15","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.10000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Valneva \/ Goldman Sachs","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ Goldman Sachs"},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"VLA1553","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Not Applicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"VLA1553","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Not Applicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Aluminium Hydroxide","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Not Applicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"VLA1553","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Not Applicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"VLA1553","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Valneva \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ Pfizer Inc"},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"VLA1553","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Not Applicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"VLA2001","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Not Applicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"VLA1553","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Not Applicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Deerfield Management Company","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Financing","leadProduct":"VLA1553","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Valneva \/ Deerfield Management Company","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Deerfield Management Company"},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"VLA1553","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Not Applicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"VLA1553","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Not Applicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"PF-07307405","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Valneva \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ Pfizer Inc"},{"orgOrder":0,"company":"Valneva","sponsor":"United States Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Agreement","leadProduct":"Inactivated Adsorbed Japanese Encephalitis Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0.029999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"Valneva \/ United States Department of Defense","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ United States Department of Defense"},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"VLA1553","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Not Applicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"VLA1553","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Not Applicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"Chikungunya Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Not Applicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"Chikungunya Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Valneva \/ Not Applicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Divestment","leadProduct":"Chikungunya Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0.10000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.10000000000000001,"dosageForm":"Injection","sponsorNew":"Valneva \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Undisclosed"},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"VLA1601","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Valneva \/ Not Applicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"Chikungunya Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Not Applicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"VLA1553","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Not Applicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"Chikungunya Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Not Applicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"Chikungunya Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Not Applicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"VLA15","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Valneva \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ Pfizer Inc"},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"Chikungunya Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Not Applicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"Chikungunya Vaccine, Live","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Not Applicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"Chikungunya Vaccine, Live","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Not Applicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"Chikungunya Vaccine, Live","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Not Applicable"},{"orgOrder":0,"company":"Valneva","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Funding","leadProduct":"Chikungunya Vaccine","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Valneva","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Valneva \/ CEPI","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ CEPI"},{"orgOrder":0,"company":"Valneva","sponsor":"LimmaTech Biologics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Vaccine","year":"2024","type":"Partnership","leadProduct":"S4V","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Valneva \/ Valneva","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Valneva"},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"VLA15","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Valneva \/ Pfizer Inc","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Pfizer Inc"},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"VLA15","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Valneva \/ Pfizer Inc","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Pfizer Inc"},{"orgOrder":0,"company":"Valneva","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Private Placement","leadProduct":"Chikungunya Vaccine, Live","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Valneva","amount2":0.070000000000000007,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Valneva \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ Undisclosed"},{"orgOrder":0,"company":"Valneva","sponsor":"LimmaTech Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"Shigella4V2","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Valneva \/ LimmaTech Biologics","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ LimmaTech Biologics"},{"orgOrder":0,"company":"Valneva","sponsor":"LimmaTech Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"Shigella4V2","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Valneva \/ LimmaTech Biologics","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ LimmaTech Biologics"}]
Find Clinical Drug Pipeline Developments & Deals by Valneva
Details :
Shigella4V2 is a tetravalent bioconjugate vaccine consisting of the O-antigen polysaccharide of Shigella flexneri 2a, 3a, 6 & of S. sonnei, conjugated to the Pa exotoxin A protein as carrier protein.
Details :
Shigella4V (S4V) is the world’s most clinically advanced tetravalent bioconjugate shigellosis vaccine candidate, being investigated in 9 month old infants.
Details :
The proceeds will fund the development of the Company’s clinical programs, including Ixchiq, the Phase 3 pediatric, and Phase 4 programs for the chikungunya vaccine.
Details :
The partnership of Limma with Valneva aims to advance the clinical development of Shigella4V (S4V), which is being evaluated in the mid-stage clinical trial studies for the treatment of Shigellosis.
Details :
The funding will support trials of Ixchiq Chikungunya Vaccine in vulnerable groups, such as children and pregnant women. It is already approved for use in adults 18 years of age and older.
Details :
VLA15, an alum-adjuvanted formulation administered intramuscularly, is a vaccine candidate currently undergoing clinical development for the treatment of Lyme disease.
Details :
Ixchiq (Chikungunya Vaccine, Live) Intramuscular Injection is a vaccine indicated for the prevention of disease caused by chikungunya virus (CHIKV) in individuals 18 years of age and older.
Details :
Ixchiq (Chikungunya Vaccine, Live) Intramuscular Injection is a vaccine indicated for the prevention of disease caused by chikungunya virus (CHIKV) in individuals 18 years of age and older.
Details :
Ixchiq (chikungunya vaccine, live), a vaccine indicated for the prevention of disease caused by chikungunya virus in individuals 18 years of age and older.
Reset All
